Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043011 | 0.85 | TSHR (0.58) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL1691827 | 0.83 | TSHR (0.61) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL18640775 | 0.79 | TSHR (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL95925 | 0.79 | TSHR (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL13557891 | 0.79 | KDM4E (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL10425265 | 0.79 | TSHR (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL20043261 | 0.79 | TSHR (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL6531372 | 0.79 | KDM4E (0.61) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL95926 | 0.79 | KDM4E (0.56) | TSHRKDM4EPOLBCA1CA2 | |
| SCHEMBL29108931 | 0.79 | KDM4E (0.61) | TSHRKDM4EPOLBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | claimed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | TSHR 3427/4885KDM4E 1604/4885POLB 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.